Clinical Trial Update: Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating a single dose of ILV-095 in adults with plaque psoriasis was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• ILV-095

Snippet

Sponsor: Pfizer | Conditions: Plaque Psoriasis | Phase 1 | Status: TERMINATED | Results posted: 2024-07-03